Datapoint: FDA Approves Abecma for Multiple Myeloma

The FDA last week approved Bristol Myers Squibb’s and bluebird bio’s Abecma for the treatment of multiple myeloma in patients who have not responded to at least four previous rounds of treatment. Abecma is the first CAR-T cell therapy approved for multiple myeloma. This is the second CAR-T therapy for Bristol Myers, following Breyanzi’s lymphoma nod in February. Early data shows Breyanzi is currently covered for 9% of all insured lives, with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 3/29/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 26

Datapoint: J&J Sees Potential Stelara Rival in Alvotech-Teva Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 25

Datapoint: Ohio Counties Offer the Most Medicare Advantage Plans

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 24

Datapoint: Dupixent Scores First-in-Class EoE Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today